Head-To-Head Analysis: Avid Bioservices (NASDAQ:CDMO) versus Its Rivals

Avid Bioservices (NASDAQ: CDMO) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its rivals? We will compare Avid Bioservices to similar companies based on the strength of its institutional ownership, dividends, analyst recommendations, earnings, valuation, profitability and risk.

Volatility and Risk

Avid Bioservices has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500. Comparatively, Avid Bioservices’ rivals have a beta of 1.09, meaning that their average stock price is 9% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Avid Bioservices and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avid Bioservices 0 0 1 0 3.00
Avid Bioservices Competitors 172 842 1854 61 2.62

Avid Bioservices presently has a consensus target price of $10.00, indicating a potential upside of 207.69%. As a group, “Biopharmaceuticals” companies have a potential upside of 4.27%. Given Avid Bioservices’ stronger consensus rating and higher possible upside, research analysts plainly believe Avid Bioservices is more favorable than its rivals.

Profitability

This table compares Avid Bioservices and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avid Bioservices -98.76% -114.08% -56.61%
Avid Bioservices Competitors -13,493.53% -57.13% -26.30%

Earnings and Valuation

This table compares Avid Bioservices and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Avid Bioservices $57.63 million -$28.15 million -4.64
Avid Bioservices Competitors $631.32 million $62.30 million 72.14

Avid Bioservices’ rivals have higher revenue and earnings than Avid Bioservices. Avid Bioservices is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

18.1% of Avid Bioservices shares are held by institutional investors. Comparatively, 43.1% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 2.5% of Avid Bioservices shares are held by company insiders. Comparatively, 15.0% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Avid Bioservices rivals beat Avid Bioservices on 8 of the 13 factors compared.

Avid Bioservices Company Profile

Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.

Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply